PeptideDeepDiveWhat Is Semax?
Semax is a Russian prescription intranasal peptide used for stroke-related and neurological indications. It later became popular online as a nootropic. However, the evidence for stroke recovery is much stronger than the evidence for cognitive enhancement in healthy people. The FDA has not approved Semax.
Semax is a synthetic seven-amino-acid ACTH-derived peptide used as an intranasal prescription medicine in Russia. Russian drug references list stroke and other neurological indications. PubMed-indexed clinical studies also include acute and post-stroke populations. By contrast, healthy-user nootropic claims rely much more on animal work, mechanism studies and extrapolation. In the United States, Semax is not FDA-approved. In addition, FDA staff concluded in 2026 that the available criteria weighed against adding Semax free base or Semax acetate to the 503A Bulks List.
The PeptideDeepDive Editorial Team checks human-evidence claims against PubMed-indexed studies and current US regulatory claims against FDA materials. We also separate Russian medicine status from US, UK and EU approval. We do not list a medical reviewer because we have not verified one. Finally, this guide is educational only and does not provide treatment, dosing, sourcing or legal advice.
What Is Semax Peptide?
Semax is a synthetic seven-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is based on the ACTH(4-7) fragment with a Pro-Gly-Pro tail added for stability. Russian researchers developed it as a neuroactive peptide. Today, current Russian drug references list prescription intranasal Semax products.
Semax is unusual because its Russian medicine use and its Western nootropic reputation are not the same thing. In Russia, product information lists neurological indications such as acute ischemic stroke, stroke recovery, transient ischemic attacks and some cognitive or optic-nerve conditions. However, the FDA has not approved Semax for any use in the United States.
How Is Semax Thought to Work? BDNF, TrkB & Neuroprotection
Semax mechanism research often focuses on brain-derived neurotrophic factor, or BDNF, and its TrkB receptor. For example, a rat study found that intranasal Semax increased BDNF protein and TrkB signaling in the hippocampus. Other animal ischemia studies reported changes in neurotrophin-related gene activity after Semax exposure.
However, most BDNF and TrkB evidence is preclinical. Therefore, these mechanism studies can support a biological hypothesis but cannot prove that Semax improves memory, focus or stroke outcomes in people.
What Does Semax Evidence Actually Show?
The strongest human evidence centers on ischemic stroke and stroke rehabilitation. For example, a 1997 Russian clinical study examined 30 Semax-treated patients during acute hemispheric ischemic stroke. Researchers compared them with 80 patients who received conventional therapy. The authors reported faster recovery of some neurological functions in the Semax group.
In addition, a 2018 Russian clinical study examined 110 people during early or later rehabilitation after ischemic stroke. The study linked Semax use with higher plasma BDNF and better recovery on the Barthel index. Still, these studies come from a limited research base. They do not match the scale or independent replication usually expected for medicine approval in the US or EU.
Stroke-Recovery Evidence vs Healthy-User Nootropic Claims
This distinction matters. Russian-language clinical studies in ischemic stroke and rehabilitation form the strongest human Semax evidence. By contrast, healthy-user claims about focus, memory and mental clarity rely much more on animal studies, biological mechanisms and self-reported use.
Therefore, evidence from stroke or neurological populations should not be presented as proof that Semax improves cognition in healthy people. The molecule may be scientifically interesting. However, these are different questions that require different clinical trials.
Semax Regulatory Status: Russia vs US, UK & EU
Semax has a clear regulatory split. On one hand, current Russian drug references list prescription intranasal Semax products. By contrast, Semax does not have FDA approval. We also did not identify equivalent standard medicine approval in the UK or EU sources reviewed for this guide.
Current Russian drug references list 0.1% and 1% intranasal Semax products. For example, the 1% product lists acute ischemic stroke. Meanwhile, the 0.1% product lists stroke recovery, transient ischemic attacks and other neurological uses. Both are shown as prescription medicines.
The FDA has not approved Semax. Its earlier 503A nominations were withdrawn. However, FDA chose to evaluate Semax free base and Semax acetate on its own initiative in 2026. FDA staff concluded that the available criteria weighed against adding either substance to the 503A Bulks List.
We did not identify a standard UK marketing authorisation for Semax in the MHRA medicine sources reviewed for this guide. Therefore, Russian medicine status does not count as UK approval.
We did not identify a standard EMA or Irish HPRA medicine authorisation for Semax in the regulator sources reviewed here. However, national rules on import, supply and unlicensed medicines can differ. So, this is not legal advice.
Semax is not FDA-approved. FDA’s 2026 briefing says the earlier nominations were withdrawn and that FDA evaluated Semax free base and Semax acetate on its own initiative. The agency’s staff review concluded that the available evidence weighed against adding either substance to the 503A Bulks List. In addition, the Pharmacy Compounding Advisory Committee discussed Semax on July 24, 2026. However, advisory input is not the same as final FDA approval or final rulemaking.
Semax vs Selank: What’s the Difference?
People often group Semax and Selank together because both came from Russian peptide research and both appear in intranasal products. However, they are different molecules. Semax is ACTH-derived, and researchers more often study stroke recovery, neuroprotection and cognitive pathways. By contrast, Selank is tuftsin-derived, and researchers mainly study anxiety-related and GABA-linked effects.
For more context, read our Selank peptide evidence and legal-status guide. In addition, see our Semax vs Selank comparison.
What Is Still Unknown About Semax?
- Whether larger independent trials can reproduce the reported stroke-recovery findings
- Whether Semax improves focus or memory in healthy people under controlled trial conditions
- How long-term safety compares across different patterns of use
- How product purity and strength vary across unregulated research products sold online
- What final FDA rulemaking will say about Semax free base and Semax acetate
Overall, Semax has more human clinical evidence than many research peptides. However, most of that evidence relates to stroke or neurological recovery in Russia. Therefore, its nootropic reputation in healthy users should not be treated as equally well supported.
Semax Peptide FAQ
Is Semax FDA-approved?
No. The FDA has not approved Semax. In addition, FDA staff concluded in 2026 that the available criteria weighed against adding Semax free base or Semax acetate to the 503A Bulks List.
Is Semax legal in the US, UK or EU?
Semax does not have standard FDA, MHRA or EMA medicine approval. However, each jurisdiction applies different rules to possession, import, research sale and unlicensed supply. Therefore, “not approved” does not mean the same thing in every legal setting.
What is Semax used for in Russia?
Current Russian drug references list prescription intranasal Semax products for neurological uses. For example, the 1% product lists acute ischemic stroke. Meanwhile, the 0.1% product includes stroke recovery and transient ischemic attacks.
Does Semax have human clinical evidence?
Yes, but the evidence is concentrated in Russian stroke and rehabilitation studies. For example, PubMed indexes a 30-patient acute-stroke study and a 110-patient post-stroke rehabilitation study. However, this does not establish strong evidence for nootropic use in healthy people.
What is the difference between Semax and Selank?
Semax is ACTH-derived, and researchers more often study stroke recovery, neuroprotection and cognitive pathways. By contrast, Selank is tuftsin-derived, and researchers mainly study anxiety-related and GABA-linked effects.
References
- Gusev, E.I. et al. (1997), Effectiveness of Semax in the acute period of hemispheric ischemic stroke — Russian clinical study with 30 Semax-treated patients and an 80-patient conventional-therapy comparison group.
- Gusev, E.I. et al. (2018), The efficacy of Semax in the treatment of patients at different stages of ischemic stroke — clinical study involving 110 post-stroke patients.
- Dolotov, O.V. et al. (2006), Semax regulates BDNF and TrkB expression in the rat hippocampus — preclinical BDNF/TrkB mechanism study.
- Dmitrieva, V.G. et al. (2010), Semax and Pro-Gly-Pro activate neurotrophin and receptor-gene transcription after cerebral ischemia — rat ischemia model.
- U.S. Food and Drug Administration (2026), FDA Evaluation of Semax-Related Bulk Drug Substances — FDA staff briefing for Semax free base and Semax acetate.
- U.S. Food and Drug Administration (2026), July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting — Semax-related substances were discussed on July 24.
- U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — Semax appears among withdrawn nominations with FDA safety concerns.
- Vidal Russia, Semax 0.1% nasal drops — current Russian prescription-drug reference with stroke-recovery and neurological indications.
- Vidal Russia, Semax 1% nasal drops — current Russian prescription-drug reference for acute ischemic stroke.
- Medicines and Healthcare products Regulatory Agency, Find product information about medicines — official UK medicine product-information search guidance.
- Health Products Regulatory Authority, Find a Medicine — Irish authorised-medicine search.